We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+2.91%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.76B
AUM Growth
-$153M
Cap. Flow
-$27.1M
Cap. Flow %
-1.54%
Top 10 Hldgs %
72.57%
Holding
43
New
2
Increased
20
Reduced
8
Closed
1

Top Buys

Rank Stock Value
1
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$31.7M
2
EHTH icon
eHealth
EHTH
+$30.1M
3
BIIB icon
Biogen
BIIB
+$29.4M
4
FOLD
Amicus Therapeutics
FOLD
+$29.3M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$14.6M

Top Sells

Rank Stock Value
1
STAA icon
STAAR Surgical
STAA
+$104M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$41.5M
3
UTHR icon
United Therapeutics
UTHR
+$16.4M
4
INSM icon
Insmed
INSM
+$10.8M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.1%
2 Financials 4.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$29B
$198M 11.3%
5,824,507
-281,473
-5% -$10.8M
STAA icon
2
STAAR Surgical
STAA
$1.25B
$191M 10.89%
1,813,911
-1,035,437
-36% -$104M
ABMD
3
DELISTED
Abiomed Inc
ABMD
$183M 10.45%
575,233
+18,600
+3% +$5.95M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$13.4B
$167M 9.49%
2,205,750
+50,700
+2% +$4.14M
UTHR icon
5
United Therapeutics
UTHR
$22.4B
$115M 6.55%
687,206
-98,200
-13% -$16.4M
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$96.4M 5.49%
9,761,043
+1,893,929
+24% +$29.3M
BIIB icon
7
Biogen
BIIB
$30.4B
$96M 5.47%
343,200
+108,900
+46% +$29.4M
RVNC
8
DELISTED
Revance Therapeutics, Inc.
RVNC
$89.5M 5.1%
3,201,866
+528,553
+20% +$14.6M
EHTH icon
9
eHealth
EHTH
$39.1M
$77M 4.39%
1,058,370
+471,371
+80% +$30.1M
ACAD icon
10
Acadia Pharmaceuticals
ACAD
$5.07B
$60.3M 3.44%
2,337,877
+36,400
+2% +$1.6M
EPZM
11
DELISTED
Epizyme, Inc
EPZM
$59.7M 3.4%
6,856,513
+117,600
+2% +$1.22M
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$295M
$57M 3.25%
3,791,805
-438,743
-10% -$7.1M
KPTI icon
13
Karyopharm Therapeutics
KPTI
$47.1M
$56.4M 3.22%
357,577
+6,400
+2% +$1.35M
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$44.9M 2.56%
600,500
+10,300
+2% +$844K
PRTA icon
15
Prothena Corp
PRTA
$468M
$43.8M 2.49%
1,742,505
+50,700
+3% +$954K
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
$36M 2.05%
235,276
-268,153
-53% -$41.5M
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
$31.5M 1.79%
4,484,411
+15,000
+0.3% +$101K
ALGN icon
18
Align Technology
ALGN
$12.4B
$30M 1.71%
55,405
-12,100
-18% -$6.69M
GRTS
19
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$21.7M 1.23%
+2,298,382
New +$31.7M
GOSS icon
20
Gossamer Bio
GOSS
$89.3M
$16.4M 0.93%
1,772,950
+33,900
+2% +$342K
PBYI icon
21
Puma Biotechnology
PBYI
$454M
$13.5M 0.77%
1,392,997
+19,100
+1% +$213K
ANAB icon
22
AnaptysBio
ANAB
$1.69B
$9.41M 0.54%
436,592
+20,300
+5% +$512K
ALKS icon
23
Alkermes
ALKS
$8.29B
$9.1M 0.52%
487,100
+336,502
+223% +$6.89M
DRNA
24
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$8.51M 0.48%
332,713
+900
+0.3% +$23K
KLDO
25
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$6.37M 0.36%
786,400
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
CAAM
Cornerstone Advisors Asset Management Bethlehem, Pennsylvania $648M AUM 11.43% 1-Year Est. Return

Palo Alto Investors's Q1 2021 Portfolio in Review

As of Q1 2021, Palo Alto Investors held 43 positions worth $1.76B, down 8% from $1.91B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Palo Alto Investors's Q1 2021 filing shows 2 new, 20 increased, 8 reduced and 1 closed positions. Its largest new stake was Gritstone bio, Inc. Common Stock: 2,298,382 shares worth $21.7M. The largest sale was STAAR Surgical, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q1 2021 buy was Gritstone bio, Inc. Common Stock: 2,298,382 shares worth $21.7M.
  • Palo Alto Investors added most to eHealth in Q1 2021, an estimated $30.1M increase.
  • Palo Alto Investors's biggest Q1 2021 reduction was STAAR Surgical, cutting an estimated $104M.
  • Palo Alto Investors fully exited Aprea Therapeutics in Q1 2021, selling an estimated $634K.
  • Palo Alto Investors's ten largest holdings make up 73% of its $1.76B portfolio in Q1 2021.
  • Palo Alto Investors opened 2 new positions and closed 1 in Q1 2021.
  • Palo Alto Investors's portfolio value fell 8% quarter-over-quarter to $1.76B.

Based on Palo Alto Investors's 13F filing for Q1 2021, filed 17 May 2021.